⌕
Amylyx Pharmaceuticals · AMLX · Nasdaq
Tenet 55 · Mixed
Compare
$28.52−5.84%Market openTenet 55 · Mixed
$28.52−1.77 (−5.84%)
Market open · 15-min delayed · as of 1:57 PM ET· Nasdaq · USD

Amylyx Pharmaceuticals (AMLX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AMLX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 15, 2026 · 17:41 ET
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript…

AMLX −5.8% todayRead at source ↗
● Business WireNov 14, 2026 · 12:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.…

AMLX −5.8% todayRead at source ↗
● Defense WorldNov 7, 2026 · 05:36 ET
Amylyx Pharmaceuticals Q3 Earnings Call Highlights

Amylyx Pharmaceuticals (NASDAQ: AMLX) plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-s…

AMLX −5.8% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 09:14 ET
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief…

AMLX −5.8% todayRead at source ↗
● Business WireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.…

AMLX −5.8% todayRead at source ↗
● Business WireNov 4, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.…

AMLX −5.8% todayRead at source ↗
● Business WireNov 3, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.…

AMLX −5.8% todayRead at source ↗
● Business WireNov 2, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.…

AMLX −5.8% todayRead at source ↗
● Business WireOct 6, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.…

AMLX −5.8% todayRead at source ↗
● Defense WorldOct 4, 2026 · 14:14 ET
Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review

Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on…

AMLX −5.8% todayRead at source ↗
● MarketBeatOct 3, 2026 · 03:03 ET
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Applica…

AMLX −5.8% todayRead at source ↗
● Seeking AlphaSep 16, 2026 · 02:11 ET
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

AMLX −5.8% todayRead at source ↗
● The Motley FoolSep 1, 2026 · 09:30 ET
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.…

AMLX −5.8% todayRead at source ↗
● Defense WorldAug 29, 2026 · 04:57 ET
BlackRock Inc. Acquires New Stake in Amylyx Pharmaceuticals, Inc. $AMLX

BlackRock Inc. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,82…

AMLX −5.8% todayRead at source ↗
● Defense WorldAug 27, 2026 · 03:35 ET
Almitas Capital LLC Buys Shares of 974,881 Amylyx Pharmaceuticals, Inc. $AMLX

Almitas Capital LLC acquired a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund ac…

AMLX −5.8% todayRead at source ↗
● Defense WorldAug 24, 2026 · 03:47 ET
Deutsche Bank AG Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX

Deutsche Bank AG bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in a recent quarter, according to its most recent filing with the SEC. The fund bought 557,937 shares of the company's stock, valued at a…

AMLX −5.8% todayRead at source ↗
● The Motley FoolAug 21, 2026 · 17:40 ET
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.…

AMLX −5.8% todayRead at source ↗
● Business WireAug 19, 2026 · 23:06 ET
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its comm…

AMLX −5.8% todayRead at source ↗
● Business WireAug 18, 2026 · 16:01 ET
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of it…

AMLX −5.8% todayRead at source ↗
● Business WireAug 18, 2026 · 07:00 ET
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, doub…

AMLX −5.8% todayRead at source ↗
● Business WireAug 17, 2026 · 16:01 ET
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric H…

AMLX −5.8% todayRead at source ↗

No upcoming events in the feeds.

NVDA15−4.3%
UBS4−1.3%
INTC3−7.4%

Article counts from the last market-wide feed page, across every symbol we track and not just AMLX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.